|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
<b>Purpose:</b> Excess growth hormone (GH) secretion in acromegaly patients results in increased levels of IGF-1 expression, which causes the clinical manifestations of acromegaly.
|
30619084 |
2018 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
530 patients (36%) reported at least 1 acral enlargement symptom and were tested for IGF-1, 41 were above range, persisted in 7, and among those, 2 cases of acromegaly were diagnosed (prevalence of at least 1.35 cases/1000).
|
28898247 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is a disease of exaggerated somatic growth and distorted proportion arising from hypersecretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1).
|
20234189 |
2010 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is a pathological condition associated with excess growth hormone (GH) and insulin-like growth factor-I (IGF-I) and a high prevalence of diabetes, hypertension, atherosclerosis, and heart failure; resulting in premature death.
|
22370764 |
2012 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is caused by a pituitary adenoma that releases excess growth hormone (GH) and a concomitant increase in insulin-like growth factor 1 (IGF-1).
|
28660605 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is a rare disease generally brought about by a benign tumour in the pituitary and characterized by growth hormone (GH) and insulin-like growth factor 1 (IGF-1) excess.
|
28808855 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is characterized by growth hormone (GH) and insulinlike growth factor-1 (IGF-1) hypersecretion, and GH and IGF-1 play important roles in regulating body composition and glucose homeostasis.
|
28945897 |
2017 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Acromegaly is a rare disease due to chronic GH excess and to the consequent increase in IGF-1 levels.
|
30034367 |
2018 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Acromegaly is a rare disease characterized by high levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1).
|
30482010 |
2019 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is associated with increased growth hormone (GH) and insulin-like growth factor-I (IGF-I) secretion which may support tumour development and growth.
|
30742299 |
2019 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is a rare disease resulting from hypersecretion of growth hormone (GH) and insulin-like growth factor 1 (IGF1) typically caused by pituitary adenomas, which is associated with increased mortality and morbidity.
|
30843342 |
2019 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is a rare disease due to chronic excess growth hormone (GH) and IGF-1.
|
30851160 |
2019 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is known to be associated with high incidence of malignancies probably due to the mitogenic effects of IGF-1.
|
31185505 |
2019 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is characterized by an excess of growth hormone (GH) and insulin like growth-factor 1 (IGF1).
|
31751301 |
2019 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is associated with clinically high IGF-I concentrations.
|
31755099 |
2019 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IGF(CA)19 and IGFBP-3-202A/C gene polymorphism in patients with acromegaly.
|
20920870 |
2010 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
IGF-1 results may differ after switching from an older immunoassay to a consensus-compliant assay such as LC-MS. Clinicians should consider the potential impact of assay switching before altering treatment due to discrepant results, particularly in patients monitored over time, such as those with acromegaly and GH deficiency.
|
29218459 |
2018 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
IGF-1 independently correlates with the coronary microvascular impairment, suggesting the pivotal role of this hormone in explaining the increased cardiovascular risk in acromegaly.
|
29353224 |
2018 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
IGF-1-based screening reveals a low prevalence of acromegaly in patients with obstructive sleep apnea.
|
29388045 |
2018 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Insulin-like growth factor-1 (IGF-1) is a thyroid growth factor, and there is a correlation between IGF-1 levels and thyroid volume (TV) in patients with acromegaly.
|
30745501 |
2019 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Insulin-like growth factor 1 (IGF-1) assay should be used as a screening test whenever acromegaly is suspected.
|
30843181 |
2019 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) levels are the main targets for monitoring acromegaly activity, but they are not in close relationship with the clinical course of the disease and the associated comorbidities.
|
31561638 |
2019 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
A low secretory activity of these tumours might explain the normal plasma values for GH and insulin-like growth factor 1 (IGF1) and the absence of clinical signs of acromegaly.
|
27913611 |
2017 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A phase III trial of oral octreotide capsules demonstrated that this treatment can safely sustain suppressed levels of GH and IGF-1 and reduce the severity of symptoms in patients with acromegaly previously controlled by injectable SRL therapy, with the added benefit of no injection-site reactions.
|
26610414 |
2016 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A retrospective observational study was conducted in patients with acromegaly to analyze IGF1 and IGFBP3 gene polymorphisms.
|
25385818 |
2015 |